Cannabis in Adults with Cancer
Publication Date: March 12, 2024
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
Treatmen...
...inical Communication and Ed...
...dation 1.1Health systems and clinicia...
...ation 1.2Given the high prevalence o...
...ecommendation 1.3When adults with cancer...
...er Treatment
...n 2.1Clinicians should recommend against...
...dation 2.2Clinicians should recommend...
...Treatment-related Toxicity, Symptom...
...commendation 3.1...
...inol and nabilone] (EB, , M, Weak)349937...
...r 1:1 THC:CBD extract] (EB, , L,...
...on 3.2Outside of a clinical trial, clinicians...
...commendation 3.3Evidence remains insufficien...
.... Taking an In-depth History of Cannabis a...
...ary of Recommendations Pertaining to Use o...
...General Safety AwarenessHaving troub...
...e 1. Endocannabinoid System...
...es that cancer clinical trials are vital to...